Stockscreener 앱 받기
126.20
0.05%
-0.06
시간 외 거래:
126.08
-0.12
-0.10%
전일 마감가:
$126.26
열려 있는:
$126.65
하루 거래량:
5.90M
Relative Volume:
3.55
시가총액:
$13.41B
수익:
$612.78M
순이익/손실:
$-86.37M
주가수익비율:
-145.06
EPS:
-0.87
순현금흐름:
$-62.91M
1주 성능:
+33.02%
1개월 성능:
+45.12%
6개월 성능:
+64.95%
1년 성능:
+91.36%
1일 변동 폭
$126.16
$126.73
1주일 범위
$126.00
$128.00
52주 변동 폭
$62.78
$128.00
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
명칭
Intra Cellular Therapies Inc
전화
(646) 440-9333
주소
135 ROUTE 202/206, BEDMINSTER, NY
ITCI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
126.20 | 13.41B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-11 | 개시 | TD Cowen | Outperform |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2022-08-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-22 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 개시 | Goldman | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-10 | 개시 | Goldman | Buy |
| 2020-02-20 | 개시 | Evercore ISI | Outperform |
| 2020-01-31 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-12 | 개시 | Jefferies | Buy |
| 2018-02-26 | 개시 | JP Morgan | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-11-08 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-09-07 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-09-29 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-09-29 | 다운그레이드 | SunTrust | Buy → Neutral |
모두보기
Intra Cellular Therapies Inc 주식(ITCI)의 최신 뉴스
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders - Morningstar
3,043 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Avanza Fonder AB - MarketBeat
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales - MSN
Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Week’s Rally - Insider Monkey
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Oak Ridge Investments LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Assenagon Asset Management S.A. Has $12.20 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Jim Cramer on Intra-Cellular Therapies, Inc. (ITCI): ‘Intra-Cellular Had Something’ - Insider Monkey
Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires - Insider Monkey
J&J to Acquire Intra-Cellular for About $14.6 Billion - MSN
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer - MSN
Is Johnson & Johnson Stock Set to Reward Long-Term Holders? - Benzinga
Johnson & Johnson exploring takeover of Intra-CellularBloomberg - MSN
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? - MSN
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - MSN
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports - MSN
Why Intra-Cellular (ITCI) Led the Monday Upsurge? - MSN
These Stocks Are Moving the Most Today: Micron, Intra-Cellular Therapies, and More - MSN
J&J to acquire psychiatric drugs maker Intra-Cellular for $14.6 billion - MSN
Intra-Cellular Therapies (NASDAQ:ITCI) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World
Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies - MSN
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders - MSN
J&J to buy Intra-Cellular for $132/share in cash - MSN
J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal - MSN
Johnson & Johnson Is Exploring Bid for Intra-Cellular Therapies - MSN
Why Johnson & Johnson Is Buying Intra-Cellular Therapies In A $14.6 Billion Deal - Pulse 2.0
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn - BioXconomy
J&J’s Top Rating at Risk Because of Intra-Cellular Deal - Bloomberg
Johnson & Johnson to acquire Intra-Cellular Therapies for $14.6bn - World Pharmaceutical Frontiers
Baird R W Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Hold - MarketBeat
Leerink Partnrs Downgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Hold - MarketBeat
Cantor Fitzgerald Upgrades Intra-Cellular Therapies (NASDAQ:ITCI) to Strong-Buy - MarketBeat
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK And Intra-Cellular - Barchart
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular - Yahoo Finance
Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion - European Biotechnology News
Piper Sandler Downgrades Intra-Cellular Therapies (ITCI) - MSN
JnJ to acquire Intra-Cellular Therapies for USD 14.6 billion - Medical Dialogues
J&J strikes $14.6 billion deal for Intra-Cellular Therapies - MSN
Johnson & Johnson's 'AAA' rating on Credit Watch Negative at S&P following Intra-Cellular Therapies acquisition - Investing.com
J&J Is in Talks to Buy $10 Billion Biotech Intra-Cellular - MSN
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference - Yahoo Finance
Johnson & Johnson Bolsters Neuroscience Offerings with $14.6 Billion Acquisition of Intra-Cellular Therapies - Hoodline
Johnson & Johnson to Expand Neuroscience Portfolio with US$14.6 Billion Acquisition - Investing News Network
Intra-Cellular Therapies' (ITCI) Neutral Rating Reiterated at Piper Sandler - MarketBeat
J&J to leverage Intra-Cellular Therapies’ neurology portfolio - Yahoo Finance
Intra-Cellular Therapies (NASDAQ:ITCI) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Johnson & Johnson acquires Intra-Cellular for $14.6bn - OutSourcing-Pharma.com
Cravath, Davis Polk advise on Johnson & Johnson’s $14.6bn Intra-Cellular acquisition - The Global Legal Post
Intra-Cellular Therapies stock jumps 34%: Can it ride the wave? - Dataconomy
ITCI Poised for Turnaround Amid Rising Mental Health Concerns - Yahoo Finance
J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition - PMLiVE
Intra Cellular Therapies Inc (ITCI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
0.94%
자본화:
|
볼륨(24시간):